MOJ
eISSN: 2381-179X
Submit manuscript...
Editorial Volume 16 Issue 2
Medicinal Cannabis in supportive breast cancer care: cannabinoids for chemotherapy-associated symptoms and topical applications
Patricia Beck Eichler-Barker
Received: May 13, 2026 | Published: May 15, 2026
Citation: Eichler-Barker PB. Medicinal cannabis in supportive breast cancer care: cannabinoids for chemotherapy-associated symptoms and topical applications. MOJ Clin Med Case Rep. 2026;16(2):41-42. DOI: 10.15406/mojcr.2026.16.00497
Abstract
Medicinal Cannabis has emerged as a complementary therapeutic strategy in oncology supportive care, particularly for patients experiencing chemotherapy-associated adverse effects. In breast cancer management, cannabinoids are increasingly investigated for their ability to alleviate nausea, vomiting, neuropathic pain, sleep disturbances, anxiety, and inflammatory symptoms. The biological basis of these effects involves modulation of the endocannabinoid system (ECS), a regulatory signaling network involved in nociception, immune responses, mood regulation, and physiological homeostasis. 1 This paper reviews current evidence regarding oral and topical cannabinoid formulations in supportive breast cancer care. Particular attention is given to full-spectrum Cannabis extracts containing Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and terpenes, as well as topical cannabinoid creams formulated with coconut cream, shea butter, and medium-chain triglyceride (MCT) oil. An integrative supportive protocol involving oral full-spectrum THC extract (5%) administered three times daily, oral CBD extract (2.5%) twice daily, topical full-spectrum cream applied to the hands and feet, and evening CBD cream application is discussed in the context of chemotherapy-induced peripheral neuropathy and inflammatory symptom management. Current evidence supports medicinal Cannabis primarily as a supportive intervention aimed at improving quality of life rather than as a curative therapy for breast cancer itself.2
Keywords: cannabidiol, nociception, cancer, chemotherapy, Protocol
©2026 Eichler-Barker. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.